943994-02-3

Usage

Uses

Used in Pharmaceutical Industry:
TMDPBO is used as a synthetic reagent for the creation of complex molecules in the pharmaceutical industry. Its role in the Suzuki-Miyaura cross-coupling reaction is pivotal for developing new drugs with enhanced efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, TMDPBO is employed as a key component in the synthesis of novel agrochemicals. Its contribution to the formation of carbon-carbon bonds is essential for the development of effective and targeted pesticides and other agricultural chemicals.
Used in Organic Synthesis:
TMDPBO is utilized as a reagent in organic synthesis, particularly for the Suzuki-Miyaura cross-coupling reaction. This reaction is fundamental for the construction of various organic compounds, including those with potential applications in materials science, medicinal chemistry, and other specialized fields.
Used in Research and Development:
TMDPBO is also used in research and development settings, where its properties and reactivity are explored to discover new synthetic pathways and improve existing ones. Its stability and effectiveness make it an ideal candidate for probing the limits of cross-coupling reactions and expanding the scope of synthetic chemistry.

InChI:InChI=1/C14H18BNO4/c1-13(2)14(3,4)20-15(19-13)9-5-6-11-10(7-9)16-12(17)8-18-11/h5-7H,8H2,1-4H3,(H,16,17)

Upstream product

• 40925-68-6 2-amino-4-bromo-phenol 
• 24036-52-0 6-bromo-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1246765-28-5 (3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)boronic acid 
• 1221500-75-9 6-[5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 1221501-08-1 6-(1-ethyl-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl)-2H-1,4-benzoxazin-3(4H)-one 
• 1221501-09-2 6-[5-(4-fluorophenyl)-3-methyl-1-propyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 1221501-62-7 6-[1-benzyl-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 1221500-38-4 6-[5-(4-fluorophenyl)-1-(3-hydroxypropyl)-3-methyl-1Hpyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 1221503-12-3 6-{1-[4-(benzyloxy)butyl]-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl}-2H-1,4-benzoxazin-3(4H)-one 
• 1221501-45-6 6-[5-(4-Fluorophenyl)-3-methyl-1-(3-oxopentyl)-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 1221500-53-3 6-[1-(2,2-difluorobutyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 1221501-23-0 3-[5-(4-fluorophenyl)-3-methyl-4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1H-pyrazol-1-yl]propanenitrile 
• 1221501-22-9 N-{2-[5-(4-fluorophenyl)-3-methyl-4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1H-pyrazol-1-yl]ethyl}methanesulfonamide 
• 1221501-21-8 N-{2-[5-(4-fluorophenyl)-3-methyl-4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1H-pyrazol-1-yl]ethyl}acetamide 
• 1221500-45-3 6-[5-(4-fluorophenyl)-3-methyl-1-(4,4,4-trifluorobutyl)-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 1221501-69-4 6-[1-(4-Fluorobenzyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one 

Relevant academic research and scientific papers

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocycl

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

Provided are certain pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as inhibitors of SHP

SYK INHIBITORS

The present disclosure a Syk compound inhibitors, including state cancer and inflammation and various disease States thereof in the treatment of relates to the use of. In one aspect a particular embodiment, . given by formula I which is marked as a chemical structure of compound. In formula said, X 1, X 2, X 3, R 2, R 3, R 4, R 5, and Y has described herein is. The present disclosure of a formula I compounds or a pharmaceutically acceptable salt of pharmaceutical compositions including, mediated by Syk and to treat conditions a employing these compounds and compositions further provides a method. (by machine translation)

ANTI-FIBROTIC PYRIDINONES

This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses methods of preparing these polycyclic compounds, pharmaceutical compositions and medicaments comprising said compounds and methods to treat, prevent or diagnose diseases, disorders or conditions associated with fibrosis.

Fused Pyrazoles as FGFR Inhibitors

The present invention relates to fused pyrazole derivatives, and pharmaceutical compositions including the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS

The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.